faricimab


( Last Updated : October 4, 2022)
Generic Name:
faricimab
Project Status:
Active
Therapeutic Area:
Diabetic Macular Edema
Manufacturer:
Hoffmann-La Roche Canada
Brand Name:
Vabysmo
Project Line:
Reimbursement Review
Project Number:
SR0729-000
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the treatment of Diabetic Macular Edema (DME).
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
For the treatment of Diabetic Macular Edema (DME).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open24-Feb-22
Call for patient/clinician input closed14-Apr-22
Clarification:

- Patient input submission received from Fighting Blindness Canada, The Canadian Council of the Blind, CNIB, Vision Loss Rehabilitation Canada, Diabetes Canada

Submission received24-Mar-22
Submission accepted07-Apr-22
Review initiated08-Apr-22
Draft CADTH review report(s) provided to sponsor for comment23-Jun-22
Deadline for sponsors comments05-Jul-22
CADTH review report(s) and responses to comments provided to sponsor12-Aug-22
Expert committee meeting (initial)24-Aug-22
Draft recommendation issued to sponsor07-Sep-22
Draft recommendation posted for stakeholder feedback15-Sep-22
End of feedback period29-Sep-22
Final recommendation issued to sponsor and drug plans13-Oct-22
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)27-Oct-22
CADTH review report(s) posted